Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

EXPLAINED: Atec - The Real Truth

IDEAYA Biosciences Says Melanoma Drug on Track for NDA After Strong Trial Data

IDEAYA Biosciences (NASDAQ:IDYA) said its lead oncology program remains on track for a regulatory submission after reporting positive top-line data in first-line metastatic melanoma, while also highlighting several pipeline programs during a presentation at the Bank of America Global Healthcare Conf

MarketBeat

One in four humanities students in Australia to take more than 25 years to pay off student loans, Treasury finds

Job-ready graduates program will also leave almost two-thirds of humanities and creative arts students with debts exceeding $50,000

The Guardian - AU

$50,000 arts degrees look set to stay, despite a new bill trying to slash uni fees

For five years, many Australian university students have been watching the amount they have to pay for their studies with alarm and despair.

The Conversation

From analysis to the latest developments in health,
read the most diverse news in one place.

Labor accused of avoiding promise to rein in controversial Morrison-era university fees scheme

Greens amendments to let new tertiary education watchdog scrutinise uni fees and the Jobs-Ready Graduates scheme rejected by federal government

The Guardian - AU

A Decade From Now, You'll Regret Not Buying This 1 Small-Cap Stock

The best long-term winners often start small.

Barchart

Nearly 20% fewer lower socioeconomic students studying law as Pocock calls to scrap Morrison-era job-ready scheme

Experts say the Morrison-era Job-ready Graduates scheme has instead had a ‘devastating impact’ on the very people higher education needs to serve

The Guardian - AU

The Insider Report: Prepare for the Next Dip Buying Opportunity

Stocks finished mixed last week, with only the tech-heavy Nasdaq finishing lower by 0.45%. The SP 500 and Dow Jones Industrial Average squeezed out gains, finishing up 0.08% and 0.34%, respectively. There's a defensive rotation taking place right now, and a lot of the high-flying momentum names have come down…

Benzinga

Read news from The Economist, FT, and more,
with one subscription

David Pocock condemns delay in establishing job ready graduates body to end $50,000 arts degrees

Senator accuses the government of not treating reform with ‘urgency it deserves’ – with no modelling done on the cost of reversing or replacing the JRG scheme

The Guardian - AU

Labor MPs urge government to prioritise reform of ‘failed’ job-ready university graduates scheme

Morrison-era program increased costs for subjects such as arts and law, while lowering course fees for degrees in Stem

The Guardian - AU

Buy Now or Regret Later: This Small-Cap Stock Has Big Disruption Potential

This small-cap biotech might be volatile in the short term but could offer genuine long-term upside with its disruptive innovation.

Barchart

Why This Beaten Down Biotech Stock Might Be a Hidden Gem

Alphatec stock is risky, but if held for the long term, shares could prove to be a lucrative opportunity.

Barchart

A Decade From Now, You'll Wish You'd Bought This Underappreciated Growth Stock

Alphatec stock could be a rewarding long-term investment if you are willing to handle the short-term volatility.

Barchart

1 ‘Strong Buy’-Rated Growth Stock Wall Street Expects to Soar 140%

This growth stock is down from its all-time high, but analysts are forecasting around 140% upside based on Wall Street’s high price target.

Barchart

‘Band-aid’: debt relief fails to address inequitable pricing of degrees, university students say

Albanese’s plan is viewed as a ‘last-ditch effort’ to win votes but students also want the vexed jobs ready graduate scheme reversed

The Guardian - AU

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

Insiders Are Buying the Dip in Alphatec Stock, Should You?

ATEC cratered hard after its latest earnings report, but insiders bought the dip. Here's a closer look.

Barchart

A Decade from Now, You'll Wish You Had Bought This Growth Stock

Strong revenue growth and product innovations have Wall Street believing that this growth stock will rally 114% over the next 12 months.

Barchart

1 'Strong Buy' Growth Stock That Analysts Expect to Double

This growth stock has tumbled in recent months, but analysts are forecasting more than 100% upside, based on Wall Street's mean price target.

Barchart

1 'Strong Buy' Growth Stock Wall Street Expects to Soar Around 70%

Alphatec's revenue growth could lead to the company becoming profitable, causing the stock to rally. However, there are risks.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Alphatec Holdings's Return On Capital Employed Insights

According to data from Benzinga Pro, during Q4, Alphatec Holdings's (NASDAQ:ATEC) reported sales totaled $73.96 million. Despite a 6.61% increase in earnings, the company posted a loss of $40.19 million.

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Rivian Automotive Inc

Read news from The Economist, FT, and more,
with one subscription

Topics

Dow Jones Industrial Average

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.